Zentalis Pharmaceuticals, Inc.

ZNTL

Find Out if You Qualify for a Financial Reward by filling out the form below.

Zentalis Pharmaceuticals, Inc. Form












Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Zentalis announced on June 18, 2024, that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).”

Following this news, Zentalis’s stock price fell over 50% on June 18, 2024.

Active Cases

Ticker Symbol Company Name Join Deadline Join
WOLF Wolfspeed, Inc. January 17, 2025 Join
SUI Sun Communities, Inc. February 10, 2025 Join
SAVA Cassava Sciences, Inc. February 10, 2025 Join
APLT Applied Therapeutics, Inc. February 18, 2025 Join